Even in non-oncogene driven but high PD-L1 expressing tumours, ~70% of patients treated with first line immunotherapy still relapse and die of their disease50, underscoring the dynamic role of the tumour microenvironment and the need, not only to better predict the emergence of resistance, but also to develop strategies to abrogate its development. The gene discussed is CD274; the disease is neoplasm.